Chargement en cours...
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS p...
Enregistré dans:
| Publié dans: | Mult Scler Relat Disord |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier B.V.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7428688/ https://ncbi.nlm.nih.gov/pubmed/32823148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102452 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|